Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment
ResearchMoz added Latest Research Report titled " Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth " to it's Large Report database.
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 85-95% of all diabetics have T2DM.
T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=556848
Scope
The current T2DM in the Asia-Pacific (APAC) market contains novel products, including Jardiance - a SGLT-2 inhibitor; Victoza - a GLP-1 receptor agonist; and Galvus - a DPP-4 inhibitor.
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 85-95% of all diabetics have T2DM.
T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=556848
Scope
The current T2DM in the Asia-Pacific (APAC) market contains novel products, including Jardiance - a SGLT-2 inhibitor; Victoza - a GLP-1 receptor agonist; and Galvus - a DPP-4 inhibitor.
- What are the competitive advantages of the existing novel drugs?
With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes, in comparison to currently marketed products and combination therapies.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the T2DM market?
Analysis of clinical trials, since 2006, identified that the failure rates of T2DM molecules were highest in Phase II, at 54%, with the overall attrition rate for T2DM at 82.6%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html
Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 9
2.1 Disease Overview 9
2.2 Classification 9
2.3 Symptoms 10
2.4 Etiology 10
2.5 Pathophysiology 11
2.6 Epidemiology 13
2.7 Prognosis 13
2.8 Co-morbidities and Complications 14
2.9 Diagnosis 15
2.10 Assessing Treatment Effectiveness 17
2.11 Treatment 17
2.11.1 Non-insulin T2DM Therapies 19
2.11.2 Insulin T2DM Therapies 22
2.12 Treatment Segments 24
2.12.1 Non-insulin therapies 24
2.12.2 Insulin Therapies 39
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 9
2.1 Disease Overview 9
2.2 Classification 9
2.3 Symptoms 10
2.4 Etiology 10
2.5 Pathophysiology 11
2.6 Epidemiology 13
2.7 Prognosis 13
2.8 Co-morbidities and Complications 14
2.9 Diagnosis 15
2.10 Assessing Treatment Effectiveness 17
2.11 Treatment 17
2.11.1 Non-insulin T2DM Therapies 19
2.11.2 Insulin T2DM Therapies 22
2.12 Treatment Segments 24
2.12.1 Non-insulin therapies 24
2.12.2 Insulin Therapies 39
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment
![Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment]()
Reviewed by Sagar Jagtap
on
04:43
Rating:
No comments: